Axcan Pharma; the next biochempharma ?? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Axcan Pharma; the next biochempharma ??

AXP 360.73

+0.5%

Oct 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Raintown who wrote ()	9/5/1997 11:13:00 PM
From: Raintown	of 4

Hi, Axcan just went up almost 2$ in the last couples of days, any idea why ? Maybe the effect on the article in the Post yesterday ? I'm also inserting the last articles about the company. Any news on your side ? Axcan Pharma Inc - Post says First Marathon analyst likes deal Axcan Pharma Inc AXP Shares issued 12800000 1997-09-03 close $10.55 Thursday Sep 4 1997 The Financial Post reports in its Thursday edition that Montreal's Axcan Pharma is buying the Canadian rights to Warner-Lambert's Jouveinal line of gastroenterology products, in a bid to boost its sales of digestive therapies. Reporter Jennifer Lanthier says the company also closed a deal on Wednesday to acquire the US rights to the pancreatic enzyme product Viokase from American Home Products. Axcan would not put a price tag on the individual deals, but chief executive Leon Gosselin says the two acquisitions will double the company's sales. First Marathon Securities analyst Cameron Groome says the Parke-Davis division of Warner-Lambert has sold pretty much the whole gastroenterology franchise to Axcan. He says Axcan looks like it got the stuff at a pretty damn good price. The disclosure came after the market closed. Axcan shares fell $0.35 to $10.55 on Wednesday on the Montreal Exchange. Mr Groome says Axcan paid about $32 million for $18 million in revenues, which is less than two times sales, which is pretty good. (c) Copyright 1997 Canjex Publishing Ltd. canada-stockwatch.com old url (better for printing)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next